A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.

Gil Awada,Julia Katharina Schwarze,Jens Tijtgat,Giuseppe Fasolino,Hendrik Everaert,Bart Neyns

Journal of Clinical Oncology（2021）

引用 3|浏览5

暂无评分

摘要

9529Background: The mitogen-activated protein kinase (MAPK) pathway can be activated by alternative driver mutations in BRAFV600/NRASQ61R/K/L wild-type (wt) melanoma. MEK-inhibitor monotherapy has ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要